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A hereditary component to breast cancer was first described by the
Romans and clearly documented by Broca, the French surgeon,
over a hundred years ago (Broca, 1866). Although three genes
(p53, Brcal and Brca2) are now known to play a role in hereditary
breast cancer (Ford and Easton, 1995), numerous families exist
that carry no identifiable mutations in any of these genes in which
breast cancer occurs much more often than would be expected by
chance (Lynch et al, 1976; Ford and Easton, 1995). Clearly, addi-
tional heritable factors, perhaps less penetrant than Brcal, Brca2
and p53, play an important, but as yet poorly understood, part in
breast cancer aetiology (Serova et al, 1997).
In 1976, Swift published data that suggested an increased
relative risk of developing breast cancer among the members of
ataxia telangiectasia (AT) families. AT can be regarded as an
inherited cancer predisposition syndrome (Gatti, 1998) and there
is evidence to suggest that the cancer predisposition extends to
AT heterozygotes, although the magnitude and nature of the
predisposition is controversial (Easton, 1994). The absence of
clinical manifestation, and the lack of quantifiable in vitro cellular
characteristics make identifying AT carriers in the general popula-
tion unreliable (Heim et al, 1992; Scott et al, 1993; Bebb et al,
1998). Unfortunately, the size of the gene (150 Kb genomic, 13 Kb
cDNA, 66 exons) and the lack of mutational hot spots makes
screening approaches to mutation detection unwieldy to date
(Savitsky et al, 1995; Gilad et al, 1996).
Analysis of the mutational spectrum of the ataxia telangiectasia
mutated (ATM) gene reveals that a large majority of mutations
yield transcripts that would result in truncated protein products
(Gilad et al, 1996; Telatar et al, 1996) which can be detected by the
protein truncation test (PTT). This approach was used to screen a
large number of women who had developed breast cancer before
the age of forty for mutations in the ATM gene (Fitzgerald et al,
1997). Out of 401 cases, only two mutations were found, a similar
incidence to that found in the control group. More recently, Chen
et al (1998), using the same methodology, failed to confirm an
association between ATM mutations and familial breast cancer.
In contrast, Athma et al (1996) have suggested that although
ATM is important in breast cancer, it is likely manifest only in the
older population of breast cancer patients. Here we describe an
attempt to investigate the frequency of ATM mutations in a popu-
lation of ‘sporadic’ breast cancer patients of a slightly older age
group than in the Fitzgerald study. Forty-seven women diagnosed
with breast cancer were screened for ATM mutations using the
PTT; no mutations were found.
MATERIALS AND METHODS
Patient selection
A series of forty-seven patients were recruited from weekly breast
cancer clinics at the British Columbia Cancer Agency (BCCA),
Vancouver, Canada. Consent for genetic studies was obtained by
a physician using approved consent forms drawn up specifically
for the study. None of the patients were being investigated for
high-density familial breast or ovarian cancer.
Blood sampling and RNA extraction
Ten millilitres of peripheral blood were obtained from the donors
by venipuncture and collected in leucoprep (Becton Dickenson)
tubes. Total RNA was extracted from the buffy coat by a guani-
dium thiocyanate–phenol–chloroform single step reaction using
RNA extraction kits (“RNeasy”, Qiagen, California).
cDNA generation
First-strand cDNA was prepared in two separate 25 ml reactions
using a total of four reverse primers. Each reaction, in addition to
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Correspondence to: W Glickmanthe appropriate primers, contained 1 mg total RNA, 1 ´ first-strand
buffer, 20 units RNAase inhibitor, 10 mM dithiothreitol, 3 mM
dNTP and 100 units of M-MLV reverse transcriptase. The reaction
mixture was incubated for 1 h at 37°C and 5 ml of the reaction
product used as a polymerase chain reaction (PCR) template.
Primers and PCR
As previously described (Telatar et al, 1998), the ATM gene was
divided into seven overlapping regions: a (1387 bp), b (1247 bp),
c (1534 p), d (1521 bp), e (1316 bp), f (1769 bp) and g (1655 bp).
Primers were designed to include the T7 promoter sequence for
the initiation of transcription by T7 RNA polymerase. PCR of each
region was performed.
Protein truncation test
A total of 100 ng rt-PCR product was used directly as template for
the coupled in vitro transcription translation reaction using rabbit
reticulocyte lysate according to the manufacturer’s (Promega)
recommended protocol. Reactions were performed in a 12.5 ml
total volume with 6 mci of 35S-methionine as label. Products were
separated by means of 14% discontinuous SDS-PAGE at 200 volts
for 3 h. The gel was then soaked in Amplify (Amersham) for 30
min, dried and placed on X-ray film for between 6 and 48 h.
RESULTS
Patient details
Forty-seven women diagnosed with breast cancer were enrolled in
the study. Their age at diagnosis ranged from 30 to 78, mean age at
diagnosis was 53.4 years. All but four were aged over 40, and 29
of the patients fell in the age group between 40 and 59. The group
included mainly invasive ductal carcinoma of the breast. A variety
of treatment modalities, including radiation, were used in the
management of these patients. In all 47 samples screened, no
truncated products were detected. The PTT was successful in
identifying a mutation in the positive control, a known AT
heterozygote (parent of an affected individual).
DISCUSSION
Our results do not support the hypothesis that carriers of the ataxia
telangiectasia gene make up a significant proportion of the breast
cancer population. However, neither do our results exclude the
possibility that inheriting the ATM gene predisposes women to
breast cancer (Tables 1 and 2). Several additional factors may
influence the significance of the results.
First of all, the exact magnitude of the relative risk estimated for
developing breast cancer in female AT carriers and the proportion
of breast cancer cases attributable to AT heterozygosity is unclear.
Swift’s initial estimate (1976) was undermined by the low inci-
dence of breast cancer observed in his spouse control population
(Easton, 1994). His subsequent 6-year prospective analysis of
cancer incidence in 161 AT families identified a 5.1-fold increased
risk of breast cancer in female AT heterozygotes (Swift et al,
1991). Other investigators confirmed an elevated risk of breast
cancer in AT carriers (Pippard et al, 1988; Borresen et al, 1990) but
none documented a relative risk as high as Swift’s estimates. Also
uncertain is the manner in which such a predisposition would
affect the age pattern of breast cancer incidence. It may be, as
suggested by Athma et al (1996), that the ATM gene acts more like
a hereditary susceptibility factor rather than a highly penetrant
gene, becoming manifest only in an older population (Kinzler and
Vogelstein, 1997). Another malignancy in which ATM heterozy-
gosity may play a role, namely T-cell pro-lymphocytic leukaemia
(T-PLL) (Vorechovsky et al, 1997; Yuille et al, 1998) has an
average age at diagnosis of 69 years.
A third factor to consider is the efficiency of the PTT assay in
detecting ATM mutations. Initial estimates that 95% or more ATM
mutations would result in a truncated product (Gilad et al, 1996)
were later tempered to roughly 70% (Telatar et al, 1996; Chen et
al, 1998; Stankovic et al, 1998). If that is so, applying the PTT
assay for screening purposes will miss 30% of mutations despite
its very high efficiency as a test. On the other hand, in our experi-
ence, PTT identifies ATM mutations in the parents of AT patients
with equal efficiency (RA Gatti et al, unpublished data). Finally,
the frequency of the AT gene in the population is not clear.
Estimates of the incidence of AT vary between 1:40 000 (USA)
and 1:100 000 (UK) live births. Whether the gene frequency is
relatively constant worldwide or even in North America, is not
certain.
Consequently, the statistical power of our study ranges in signif-
icance depending on how these variables are put together. On the
basis of our study assuming a PTT sensitivity of 99%, it is improb-
able that AT heterozygotes make up 6.2% or more of the sporadic
breast cancer population or 6.8% of the breast cancer population
aged over 40 at diagnosis (P = 0.05). Even with a PTT sensitivity
of only 70%, it is unlikely that AT heterozygotes make up more
than 8.8% of the breast cancer population in general or 9.6% of the
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Table 1 Probability of finding no ATM mutations under different statistical
conditions: women of all ages
PTT Breast The chance of
sensitivity cancer population made observing 0 mutations
up of AT carriers (%) in 47 cases
99 5 0.09
99 10 0.007
99 15 0.0005
70 5 0.19
70 10 0.03
70 15 0.005
Table 2 Probability of finding no ATM mutations under different statistical
conditions: women aged over 40
PTT Breast The chance of
sensitivity cancer population made observing 0 mutations
up of AT carriers (%) in 47 cases
99 5 0.113
99 10 0.011
99 15 0.001
70 5 0.22
70 10 0.04
70 15 0.008
Using the following equation***:
P = 0S47 (1-sensitivity)n prevalencen (1-prevalence)47-n
1Where n is the true number of ATM mutations. **It is assumed that
specificity of PTT is 100%
47!
n!(47-n)!breast cancer population over 40 at diagnosis (P = 0.05) (Tables 1
and 2). The sample size in our study is sufficient to detect a six- to
ninefold increase of prevalence of AT heterozygotes among the
population of late onset sporadic breast cancer over the normal
level with 80% power.
The epidemiological association between heterozygosity for AT
and breast cancer has intrigued oncologists and tumour biologists
for over 20 years. The issue is clearly important and requires clari-
fication. Confirming the association would help account for the
increased incidence of breast cancer in women irradiated for
Hodgkin’s disease (Bhatia et al, 1996) and support suggestions of
a radiosensitive subgroup among breast cancer patients (Norman
et al, 1992; Lavin et al, 1994; Scott et al, 1998). It would confirm
that DNA repair and processing deficiencies, already implicated in
the aetiology of colon cancer (Lynch et al, 1997), have a role in
breast carcinogenesis as well (Scully et al, 1997; Sharan et al,
1997). Our data suggest that AT heterozygotes do not make up
more than 8.8% of the female population who develop sporadic
breast cancer but we are unable to discount the possibility that they
make up 6.2% or less of the breast cancer population. Multiple
smaller scale screening for unique mutations directed at specific
ethnic groups may be required to further assess the role of ATM in
breast cancer (Telatar et al, 1998).
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